/
Oncology
Sarcoma
130
Pipeline Programs↗
207
Active Trials↗
91
Companies Involved↗
Sarcoma is a highly competitive landscape with 130 programs across 91 companies. The most active players are GSK. 22 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical29
Phase 118
Phase 261
Phase 322
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
95 of 121 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 121 classified programs, each share of the total. Modality classified for 96% of 130 pipeline programs.
Analysis
Trial Status
696
clinical trials
Completed307 · 44%
Recruiting127 · 18%
Terminated75 · 11%
Unknown status71 · 10%
Active, not recruiting52 · 7%
Withdrawn26 · 4%
Other38 · 5%
Clinical Trials
Trial Activity
696 trials
Page 1 of 47
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)